Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Lisata Therapeutics Inc.

    NASDAQ: LSTA · Real-Time Price · USD
    2.52
    -0.04 (-1.56%)
    At close: Aug 15, 2025, 3:59 PM
    2.53
    0.40%
    After-hours: Aug 15, 2025, 04:00 PM EDT
    -1.56%
    Bid 2.46
    Market Cap 22.06M
    Revenue (ttm) 1M
    Net Income (ttm) -19.31M
    EPS (ttm) -2.23
    PE Ratio (ttm) -1.13
    Forward PE -2.13
    Analyst Strong Buy
    Ask 2.61
    Volume 30,361
    Avg. Volume (20D) 33,632
    Open 2.55
    Previous Close 2.56
    Day's Range 2.45 - 2.58
    52-Week Range 1.87 - 4.20
    Beta 0.94

    About LSTA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol LSTA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for LSTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    6 months ago
    -29.49%
    Lisata Therapeutics shares are trading lower after... Unlock content with Pro Subscription
    11 months ago
    +6.53%
    Lisata Therapeutics shares are trading higher after the company announced its first patient was treated in the second-line cholangiocarcinoma cohort of the BOLSTER trial.
    news image

    1 week ago · seekingalpha.com

    Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript

    Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David J. Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, ...

    news image

    1 week ago · proactiveinvestors.com

    Lisata Therapeutics advances lead cancer drug, expects key trial results by year-end

    Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it is making steady progress in advancing its pipeline of oncology drug candidates, with several key clinical trial readouts anticipated through ...

    news image

    1 month ago · proactiveinvestors.com

    Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results

    Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is evaluating Lisata's therapy candidate certepetide in combinat...

    news image

    1 month ago · proactiveinvestors.com

    Lisata Therapeutics expands IP with key patent covering certepetide's chemical structure and uses

    Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational drug candidate certepetide. The United States Patent and Trademark...

    news image

    1 month ago · proactiveinvestors.com

    Lisata Therapeutics and GATC advance AI-driven opioid use disorder therapy - ICYMI

    Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's deepening collaboration with GATC Health. Mazzo explained that the partnership has evolved due to the...

    news image

    1 month ago · proactiveinvestors.com

    Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer

    Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the University of Sydney, announced positive prelim...

    news image

    2 months ago · proactiveinvestors.com

    Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health

    Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate of drug development using artificial intelligence (AI)...

    Add to Watchlist